A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

Condition:   Respiratory Syncytial Virus Infections Intervention:   Drug: Nirsevimab Sponsors:   AstraZeneca;   Iqvia Pty Ltd Recruiting

Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials